Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
2006 · Nature Medicine · 2,102 citations
https://doi.org/10.1038/nm1358
G
Glenn F. Pierce
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
286
Papers
23.6K
Citations
78
h-index
185
i10-index
Glenn F. Pierce is an academic researcher from Canadian Hemophilia Society. The author has contributed to research in topics: Hemophilia Treatment and Research & Virus-based gene therapy research & Platelet Disorders and Treatments. The author has an h-index of 78, co-authored 244 publications.
ORCID: 0000-0002-3310-328XPapers by this author
worksWFH Guidelines for the Management of Hemophilia, 3rd edition
2020 · Haemophilia · 1,811 citations
https://doi.org/10.1111/hae.14046
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
2022 · Nature Medicine · 106 citations
https://doi.org/10.1038/s41591-022-01751-0
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
2015 · Cellular Immunology · 62 citations
https://doi.org/10.1016/j.cellimm.2015.12.008
First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy
2022 · Molecular Therapy · 30 citations
https://doi.org/10.1016/j.ymthe.2022.09.020
Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A
2024 · Haemophilia · 28 citations
https://doi.org/10.1111/hae.15071
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat